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Estimates of the global burden of cervical cancer associated 
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Summary
Background HIV enhances human papillomavirus (HPV)-induced carcinogenesis. However, the contribution of HIV 
to cervical cancer burden at a population level has not been quantified. We aimed to investigate cervical cancer risk 
among women living with HIV and to estimate the global cervical cancer burden associated with HIV.
Methods We did a systematic literature search and meta-analysis of five databases (PubMed, Embase, Global Health 
[CABI.org], Web of Science, and Global Index Medicus) to identify studies analysing the association between HIV 
infection and cervical cancer. We estimated the pooled risk of cervical cancer among women living with HIV across 
four continents (Africa, Asia, Europe, and North America). The risk ratio (RR) was combined with country-specific 
UNAIDS estimates of HIV prevalence and GLOBOCAN 2018 estimates of cervical cancer to calculate the proportion 
of women living with HIV among women with cervical cancer and population attributable fractions and age-
standardised incidence rates (ASIRs) of HIV-attributable cervical cancer.
Findings 24 studies met our inclusion criteria, which included 236 127 women living with HIV. The pooled risk of 
cervical cancer was increased in women living with HIV (RR 6·07, 95% CI 4·40–8·37). Globally, 5·8% (95% CI 4·6–7·3) 
of new cervical cancer cases in 2018 (33 000 new cases, 95% CI 26 000–42 000) were diagnosed in women living with 
HIV and 4·9% (95% CI 3·6–6·4) were attributable to HIV infection (28 000 new cases, 20 000–36 000). The most 
affected regions were southern Africa and eastern Africa. In southern Africa, 63·8% (95% CI 58·9–68·1) of women 
with cervical cancer (9200 new cases, 95% CI 8500–9800) were living with HIV, as were 27·4% (23·7–31·7) of women 
in eastern Africa (14 000 new cases, 12 000–17 000). ASIRs of HIV-attributable cervical cancer were more than 20 per 
100 000 in six countries, all in southern Africa and eastern Africa. 
Interpretation Women living with HIV have a significantly increased risk of cervical cancer. HPV vaccination and 
cervical cancer screening for women living with HIV are especially important for countries in southern Africa and 
eastern Africa, where a substantial HIV-attributable cervical cancer burden has added to the existing cervical cancer 
burden.
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Introduction
Although cervical cancer is one of the most preventable 
and treatable malignant diseases, it is the fourth most 
commonly detected cancer in women worldwide, with 
more than half a million new cases and 311 365 deaths 
in 2018.1 Infection with high-risk human papillomavirus 
(HPV; types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 
59) alone does not cause cervical cancer.2 Other known 
risk factors include smoking, increased parity, and 
infection with HIV.
Geographical disparities in the cervical cancer disease 
burden are stark and reflect the availability, coverage, and 
quality of preventive strategies and the prevalence of risk 
factors. Nearly nine in ten women who die from cervical 
cancer live in low-income and middle-income countries 
(LMICs).1 Inequalities are widening: observed incidence 
rates are declining most rapidly in high-income 
countries, with some countries moving towards cervical 
cancer elimination in the coming decades.3 By contrast, 
rates are increasing in some sub-Saharan African 
settings1,4 and have increased or remained relatively 
stable at high levels in several eastern European and 
western Asian countries.1,4,5
Cervical cancer is the most frequently detected cancer 
in women living with HIV and is classified as an AIDS-
defining illness.6 With the advent of antiretroviral therapy 
(ART), AIDS-related mortality has declined considerably, 
and life expectancy of people living with HIV has 
increased nearly to the same level as those without HIV.7 
As a result, the number of adult women living with HIV 
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has increased from an estimated 3·3 million in 1990 to 
18·8 million in 2018; 60% of these women live in eastern 
and southern Africa.8
Although high-burden settings for cervical cancer and 
HIV overlap, the extent of the contribution of HIV to the 
burden of cervical cancer and the proportion of cervical 
cancer cases due to co-infection with HIV have yet to be 
quantified. In this meta-analysis and modelling study, we 
aimed to provide a pooled estimate of the relative risk for 
cervical cancer among women living with HIV and 
present the estimated number of cases of cervical cancer 
among women living with HIV and attributable to HIV, 
based on UNAIDS HIV prevalence and GLOBOCAN 
2018 cancer estimates for 2018.
Methods
Identification and selection of relevant studies
We systematically searched five databases (PubMed, 
Embase, Global Health [CABI.org], Web of Science, and 
Global Index Medicus) to identify studies analysing the 
association between HIV infection and cervical cancer. 
The detailed search strategy can be found in the appendix 
(pp 3–6). In short, we used a WHO validated search 
strategy for “HIV” and “AIDS” and combined these terms 
with “cervical cancer” and standard WHO epidemio-
logical search terms (eg, “incidence” and “prevalence”). 
The search was done on April 29, 2019. We did not restrict 
our search by language or year of publication. We included 
published epidemiological studies (cohort, case-control, 
and registry linkage studies) reporting the risk of 
cervical cancer (International Classification of Diseases 
10th revision [ICD-10] code C53) as either a risk ratio (RR), 
odds ratio (OR), hazard ratio (HR), incidence rate ratio 
(IRR), or standardised incidence ratio (SIR) among 
women living with HIV compared with either women 
without HIV infection or the general female reference 
population. Our exclusion criteria were HIV status based 
on self-report and studies with fewer than four cases of 
cervical cancer.
Data extraction and risk of bias assessment
The published literature was screened for inclusion by 
two of us (DS and LFT) independently. These same 
reviewers extracted data from the included studies. 
Discrepancies were resolved by consensus between the 
two reviewers. In quantitative analyses, only one study 
per cohort was included to avoid double inclusion of 
patients. We selected the study with either the longest 
follow-up time or the largest sample size. We listed all 
studies that met inclusion criteria and studies used for 
the calculation of the pooled RR (appendix pp 7–18); for 
those excluded, we reported the main reason. The 
flowchart for study selection and the MOOSE checklist 
are in the appendix (pp 19–21). Risk of bias was assessed 
based on the Newcastle-Ottawa scale, a tool used to 
appraise observational studies.9 We classified studies as 
having a high risk of bias if scores were lower than eight 
stars. All other studies were considered as having low or 
moderate risk of bias.
Estimates of HIV prevalence and cervical cancer 
incidence for the year 2018
For the statistical modelling, HIV prevalence estimates for 
adult women (aged ≥15 years) for the year 2018 were 
obtained from UNAIDS.8 HIV prevalence estimates were 
available for 170 of 194 UN member states. Country-specific 
estimates (total number of cases and incidence rates per 
100 000) for invasive cervical cancer (ICD-10 code C53) 
provided by the International Agency for Research on 
Cancer (IARC) were available for 185 countries.1,10 Both 
data sources combined were available for 170 countries. 
The 15 countries and territories for which no HIV 
estimates were available accounted for fewer than 
1000 cases of cervical cancer in 2018 (appendix p 64) and 
Research in context
Evidence before this study
A meta-analysis published in 2007 reported an increased risk of 
cervical cancer among women living with HIV (risk ratio 5·8, 
95% CI 3·0–11·3), based on data from six high-income 
countries. No subsequent studies have been done to update 
this estimate, and no studies have extended results to 
low-income and middle-income countries.
Added value of this study
We present a pooled estimate of cervical cancer risk derived 
from 24 individual studies, which included 236 127 women 
living with HIV from four continents (Africa, Asia, Europe, and 
North America). We also provide global estimates of the 
proportion of women with cervical cancer living with HIV 
alongside the population attributable fraction and incidence 
of cervical cancer attributable to HIV infection.
Implications of all the available evidence
Women living with HIV have a substantially increased risk for 
cervical cancer when compared with women without HIV 
infection. Worldwide, roughly 6% of women with cervical 
cancer are living with HIV and just under 5% of all cases of 
cervical cancer are attributable to HIV. However, these 
proportions vary widely by region; 85% of women with cervical 
cancer and HIV live in sub-Saharan Africa, underscoring the 
major contribution of HIV to cervical cancer burden in the 
region. In countries with a high burden of both cervical cancer 
and HIV, it is vital to integrate HIV and cervical cancer care and 
vaccinate girls against human papillomavirus to secure 
long-term declines in the future disease burden.
See Online for appendix
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did not affect either the overall or regional estimates in 
our analysis.
Statistical analysis
A detailed description of our methods can be found 
elsewhere (appendix pp 23–25).11 We considered RR, OR, 
and SIR to be equivalent in our pooled estimates. 
In summary, estimates for the overall RR for cervical 
cancer and those stratified by subgroups were calculated 
using random-effects models, based on the risk estimate 
and its SE; weighting was based on an inverse variance 
method. Heterogeneity across studies was analysed by 
the I² index.
Using a simulation-based approach, we propagated 
uncertainty from estimates of the pooled RR and HIV 
prevalence to calculate the proportion of women with 
cervical cancer living with HIV for each country 
(equation 1) and the population attributable fraction 
(PAF) for each country (equation 2). Cause-specific risk 
estimates from random effects meta-analysis were 
represented as log normal (ln) distributions, from which 
10 000 samples were obtained using R (version 3.6.1). 
We represented HIV prevalence as a beta distribution 
and obtained 10 000 samples for each country. We sub se-
quently did the calculation shown for each of the 
10 000 samples to derive the country-specific population 
attri butable fraction (PAFc). HIV prevalence is country 
specific (HIV prevalencec) and the pooled RR is universal.
Multiplying the number of incident cervical cancer 
cases by the proportion of women with cervical cancer 
living with HIV and by the PAF yielded estimates for 
both the total number of new cases of cervical cancer 
among women living with HIV and the total number of 
cases of cervical cancer attributable to HIV for the year 
2018, respectively. Multiplying the incidence of cervical 
cancer per 100 000 by the PAF yielded the incidence 
rate for cervical cancer attributable to HIV (and the 
incidence rate of cervical cancer not attributable to 
HIV). We ran these analyses for all countries and 
integrated the results into regional and global estimates. 
We report the results by country, WHO region, 
UNAIDS region, and UN Africa subregion (appendix 
pp 49–60). World maps were created to display these 
estimates by country, divided into five levels, with the 
darkest shades representing the highest estimates. 
Statistical analyses were done in R (version 3.6.1) using 
the packages metafor (version 2.4-0) and rworldmap 
(version 1.3-6).
The protocol of this systematic review was published 
on PROSPERO, number CRD42019139813.
Role of the funding source 
SLG, RB, NB, and SD are staff members at WHO, and 
AIK, IB, FB, and GMC are employed at IARC. The external 
funders of the study (US Agency for International 
Development [USAID] and the US President’s Emergency 
Plan for AIDS Relief [PEPFAR]) had no role in study 
design, data collection, data analysis, data inter pre tation, 
Proportion of  
women with 
cervical cancer
living with HIV
HIV prevalencec  × pooled RR
(1–HIV prevalencec)+
(HIV prevalencec  × pooled RR)
= (1)
Population
attributable
fraction
(PAFc)
HIV prevalencec  × (pooled RR–1)
1 + HIV prevalencec  × (pooled RR–1)
= (2)
Figure 1: Risk of developing cervical cancer among women living with HIV, by type of study
Women living
with HIV (n)
Registry linkage studies
Cooksley et al, 1999 
Serraino et al, 1999 
Mbulaiteye et al, 2006 
Vogel et al, 2011 
Zhang et al, 2011 
Godbole et al, 2016 
Mayor et al 1, 2016
Mayor et al 2, 2016
Mayor et al 3, 2016
Salters et al, 2016
Hernandez-Ramirez et al, 2017 
Massad et al, 2017
Grabar et al 1, 2019
Grabar et al 2, 2019 
Grabar et al 3, 2019
Grabar et al 4, 2019
Pooled risk ratio 
Risk estimate model for registry linkage studies (df=15;  I2= 95·7%)
Cohort studies
Phelps et al, 2001
Clifford et al, 2005
Bedimo et al, 2009
Tanon et al, 2012
Abraham et al, 2013
Akarolo-Anthony et al, 2014
Chen et al, 2014
Pooled risk ratio
Risk estimate model for cohort studies (df=6;  I2=32·9%) 
Case-control studies
Sekirime et al, 2007
Kahesa et al, 2008
Holmes et al 1, 2009
Holmes et al 2, 2009 
Holmes et al 3, 2009
Adjorlolo-Johnson et al, 2010 
Jaquet et al, 2015
Mpunga et al, 2018
Pooled risk ratio
Risk estimate model for case-control studies (df=7; I2=32·9%)
Overall pooled risk ratio
Risk estimate model for all studies (df=30; I2=91·5%)
14 611
2141
8423
280
4982
11 710
502
403
313
2211
129 995
1807
28 977
28 977
28 977
28 977
871
2045
725
93
13 690
10 580
1360
33
45
16
6
10
31
127
155
2·50 (1·30–4·30)
2·80 (6·60–22·40)
2·70 (1·80–4·00)
4·00 (1·50–7·90)
68·10 (19·20–84·50)
15·70 (11·00–22·00)
47·00 (20·00–93·00)
15·00 (6·00–29·00)
9·00 (4·00–19·00)
24·18 (15·15–36·60)
3·24 (2·94–3·56)
3·31 (0·90–8·47)
5·40 (3·00–8·90)
4·40 (2·70–6·80)
3·40 (2·10–5·10)
3·30 (2·20–4·70)
7·64 (4·58–12·73)
7·99 (4·67 –13·67)
8·00 (2·90–17·40)
12·80 (2·90–57·30)
7·90 (3·80–16·70)
4·10 (2·30–6·60)
2·00 (0·40–3·50)
4·10 (1·66–8·48)
5·68 (3·97–8·12)
1·26 (0·45–3·49)
2·90 (1·40–5·90)
6·50 (2·10–19·80)
8·20 (1·30–50·00)
5·30 (1·30–21·40)
1·80 (0·60–5·30)
4·30 (2·20–8·30)
5·90 (3·80–9·20)
3·78 (2·50–5·73)
6·07 (4·40–8·37)
Cervical cancer
cases (n)
Risk ratio (95% CI)
13
10
27
6
14
23
8
8
7
22
428
4
14
20
22
31
5
6
12
153
7
8
7
116
138
150
150
150
132
258
560
0·25 0·50 1·00 2·00 4·00 8·00 16·00 32·00 64·00
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or writing of the report. DS and SD had full access to all 
data in the study. SD had final responsibility for the 
decision to submit for publication.
Results
24 studies met our inclusion criteria and provided 31 risk 
estimates, which were used to calculate the overall 
estimate (appendix pp 7–18, 21). Overall, 236 127 women 
living with HIV were included in these studies and 
2138 cases of cervical cancer were reported (among 
women living with HIV and those without HIV infection). 
At study entry, median age was 38 years (IQR 34–42) and 
median ART coverage was 40% (IQR 25–49). 
The included studies were done between 1981 and 2016 
and were located in 17 countries (including one territory) 
located on four continents: Africa (Benin, Côte d’Ivoire, 
Nigeria, Rwanda, Senegal, Tanzania, Togo, and Uganda), 
Asia (China, India, and Taiwan), Europe (France, 
Germany, Italy, and Switzerland), and North America 
(Canada and the USA). Most were registry linkage 
studies (n=11), followed by cohort studies (n=7) and case-
control studies (n=6). 19 studies (providing 26 risk 
estimates) were considered to have a high risk of bias 
based on the Newcastle-Ottawa scale.
The overall pooled risk of cervical cancer among 
women living with HIV was increased (RR 6·07, 95% CI 
4·40–8·37), based on highly heterogeneous data 
(I²=91·5%; figure 1; appendix p 22). Risk estimates 
ranged from 1·26 to 68·10, and only four estimates were 
not higher than unity in women living with HIV. 
In subgroup analyses by study design, registry linkage 
studies yielded a more than seven-fold risk for developing 
cervical cancer among women living with HIV compared 
with the general population (pooled RR 7·64, 95% CI 
4·58–12·73), and in cohort studies the pooled RR was 
more than five-fold (5·68, 3·97–8·12; figure 1). For case-
control studies, the corresponding risk was more than 
three-fold (pooled RR 3·78, 95% CI 2·50–5·73). The CIs 
of the subgroups overlapped. Figure 2 shows no sub-
stantial differences in pooled RRs for studies with 
different degrees of bias (high vs low or moderate), year 
of publication (studies published before 2013 vs those 
published in 2013 or later), country income group 
(studies done in LMICs vs high-income countries), or 
continent (appendix p 48). Since cervical cancer can be 
considered a rare outcome, corresponding measures of 
association (SIR, OR, and RR) should be similar in 
magnitude, and no differences were noted between SIRs, 
ORs, or RRs (appendix p 48). A universal RR was, 
therefore, used to calculate estimates of cervical cancer 
burden associated with HIV.
Globally, an estimated 33 000 (95% CI 26 000–42 000) 
new cases of cervical cancer occurred among women 
living with HIV, corresponding to 5·8% (95% CI 4·6–7·3) 
Figure 2: Risk of developing cervical cancer among women living with HIV, by subgroups
Meta-regression to assess interaction was not significant for risk of bias (p=0·96), year of publication (p=0·77), 
or country income group (p=0·46).
Estimate 
(n)
I2 Pooled risk ratio 
(95% CI)
Risk of bias
Low or moderate
High
Year of publication
Before 2013
2013 or later
Country income group
High income
Low or middle income
92·3%
87·8%
84·5%
93·1%
87·3%
90·0%
5·93 (2·91–12·06)
6·09 (4·22–8·77)
5·75 (3·42–9·66)
6·34 (4·19-9·59)
5·34 (3·80-7·51)
6·79 (3·89-11·84)
5
26
15
16
15
16
0·5 1·0 2·0 4·0 8·0 16·0 32·0 64·0
Number (95% CI) of new 
cervical cancer cases, 2018 
HIV prevalence 
(95% CI) in females 
aged ≥15 years 
Proportion 
(95% CI) of new 
cervical cancer 
patients living 
with HIV
Number (95% CI) of new 
cervical cancer patients 
living with HIV, 2018 
Population 
attributable fraction 
(95% CI) for HIV 
Number (95% CI) of 
cervical cancer cases 
attributable to HIV, 
2018
Global 569 847 (545 771–594 985) 0·67% (0·59–0·78) 5·8% (4·6–7·3) 33 000 (26 000–42 000) 4·9% (3·6–6·4) 28 000 (20 000–36 000)
WHO region
South-East Asia 158 692 (151 987–165 692) 0·21% (0·18–0·27) 1·4% (1·0–2·1) 2300 (1500–3300) 1·2% (0·8–1·8) 1900 (1200–2900)
Western Pacific 142 251 (136 241–148 526) 0·07% (0·06–0·08) 0·4% (0·3–0·6) 590 (420–820) 0·3% (0·2–0·5) 490 (330–720)
African 112 036 (107 302–116 978) 4·74% (4·14–5·41) 25·1% (20·1–30·7) 28 000 (23 000–34 000) 21·0% (15·6–26·8) 24 000 (18 000–30 000)
Americas 71 689 (68 660–74 851) 0·25% (0·21–0·30) 1·7% (1·1–2·4) 1200 (810–1700) 1·4% (0·9–2·1) 980 (630–1500)
European 69 114 (66 194–72 163) 0·20% (0·18–0·22) 1·5% (1·1–2·1) 1000 (730–1400) 1·2% (0·8–1·8) 860 (570–1200)
Eastern Mediterranean 15 903 (15 231–16 605) 0·06% (0·04–0·09) 0·5% (0·3–0·8) 80 (50–120) 0·4% (0·3–0·6) 60 (40–100)
UN Africa subregion
Eastern Africa 52 500 (42 840–65 052) 2·96% (2·56–3·42) 27·4% (23·7–31·7) 14 000 (12 000–17 000) 22·9% (19·8–26·4) 12 000 (10 000–14 000)
Central Africa 12 635 (9644–16 573) 1·64% (1·38–1·92) 12·3% (10·3–13·4) 1600 (1300–1800) 10·2% (8·6–12·0) 1300 (1100–1500)
North Africa 7639 (6323–9325) 0·07% (0·05–0·11) 0·5% (0·3–0·8) 40 (30–60) 0·4% (0·3–0·6) 30 (20–50)
Southern Africa 14 409 (13 371–15 564) 29·83% (27·54–31·82) 63·8% (58·9–68·1) 9200 (8500–9800) 53·2% (49·1–56·8) 7700 (7100–8200)
West Africa 31 939 (24 702–45 586) 1·39% (1·09-1·78) 9·5% (7·5–12·2) 3000 (2400–3900) 7·9% (6·2–10·1) 2500 (2000–3200)
Table: Estimated proportion of cervical cancer associated with HIV and population attributable fraction in 2018, by WHO regions and UN Africa subregions
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of 569 847 cases of cervical cancer in the year 2018 (table). 
Particularly affected was the African region, specifically 
the UN Africa subregions of southern Africa (63·8%, 
95% CI 58·9–68·1), with 9200 new cases (95% CI 
8500–9800), and eastern Africa (27·4%, 23·7–31·7), with 
14 000 new cases (12 000–17 000). In combination, these 
subregions contributed 70% of this double burden of 
HIV and cervical cancer (table). By contrast, the pro por-
tion of new cervical cancer cases was low in the Western 
Pacific region (0·4%, 95% CI 0·3–0·6), the Eastern 
Mediterranean region (0·5%, 0·3–0·8), and the South-
East Asia region (1·4%, 1·0–2·1; table).
Eswatini had the largest proportion of women with 
cervical cancer living with HIV (75·0%, 95% CI 
68·2–80·8), followed by Lesotho (69·3%, 61·7–76·0), 
Botswana (66·5%, 58·6–73·5), South Africa (63·4%, 
55·2–70·7), and Zimbabwe (52·2%, 43·5–60·9; appendix 
pp 37–43). By contrast, this proportion was less than 5% 
in 122 countries globally. In absolute terms, most 
women with cervical cancer living with HIV were from 
South Africa (8220 cases, 95% CI 7090–9320), followed 
by Tanzania (2610, 1900–3520), Mozambique (2150, 
1670–2690), Uganda (2050, 1560–2640), and Malawi 
(1790, 1370–2300; appendix pp 37–43).
In 2018, an estimated 4·9% (95% CI 3·6–6·4) of all 
cases of cervical cancer globally (28 000 cases, 95% CI 
20 000–36 000) were attributable to HIV (table), ranging 
from less than 1% in the Western Pacific region (0·3%, 
95% CI 0·2–0·5; 490 cases, 95% CI 330–720), and the 
Eastern Mediterranean region (0·4%, 0·3–0·6; 60 cases, 
40–100), to more than 20% in the African region (21·0%, 
15·6–26·8; 24 000 cases, 18 000–30 000; table). Cases of 
cervical cancer in the African region alone accounted for 
85% of cases attributable to HIV. 
Of 50 countries with the highest-ranking PAFs (appendix 
pp 37–43), 38 were in the African region, nine were in the 
Region of the Americas, and one each was in the Western 
Pacific, South-East Asia, and European regions (figure 3). 
The highest PAFs were seen for Eswatini (62·6%, 95% CI 
52·8–70·8), Lesotho (57·9%, 95% CI 47·7–66·6), Botswana 
(55·5%, 45·4–64·4), South Africa (52·9%, 42·8–61·9), 
and Zimbabwe (43·6%, 33·6–53·2). Conversely, in 
127 countries, PAFs were lower than 5% (figure 4A; 
appendix pp 37–43). Additional data, maps, and figures by 
WHO and UNAIDS regions are provided in the appendix 
(pp 27–36).
Age-standardised incidence rates (ASIRs) of cervical 
cancer attributable to HIV were highest in the southern 
and eastern Africa UN subregions (figure 4B). HIV-
attributable ASIRs were 10–20 per 100 000 in Botswana, 
Mozambique, Namibia, Tanzania, and Uganda and were 
higher than 20 per 100 000 in Eswatini, Lesotho, Malawi, 
South Africa, Zambia, and Zimbabwe. ASIRs of cervical 
cancers not attributable to HIV were higher than 10 per 
100 000 in all countries in sub-Saharan Africa and were 
higher than 20 per 100 000 in most countries in sub-
Saharan Africa (figure 4C).
Discussion
Our meta-analysis of 24 studies shows that women living 
with HIV have a six-fold higher risk of developing 
cervical cancer relative to their counterparts without HIV. 
Globally, an estimated 6% of new cervical cancer cases in 
2018 were diagnosed among women living with HIV and 
5% of all cases were attributable to HIV infection. Due 
to the substantial variation in HIV prevalence world-
wide, the proportion of women living with HIV among 
patients with cervical cancer ranged from less than 5% in 
122 countries to 40% or more in nine countries. In both 
relative and absolute terms, the southern and eastern 
Africa UN subregions bear the largest share of this 
burden, with a respective 64% and 27% of women with 
Figure 3: Estimated population attributable fraction for cervical cancer and HIV in the 50 highest ranked 
countries
Estimates are ranked from highest to lowest proportion. The figure shows data for 48 countries; data for 
Turkmenistan (European; 5–9·99%) and Trinidad and Tobago (Americas; <5%) are not shown because HIV 
estimates are not published by UNAIDS. 
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cervical cancer living with HIV in these regions. 
According to our estimates, six countries—namely 
Malawi, Mozambique, South Africa, Tanzania, Uganda, 
and Zimbabwe—accounted for about half of all women 
living with HIV who developed cervical cancer in 2018. 
Although HIV is an important contributor to the burden 
Figure 4: Maps showing cases of cervical cancer attributable, or not, to HIV
(A) Population attributable fraction of women with cervical cancer living with HIV in 2018. (B) ASIR attributable to HIV (per 100 000) in 2018. (C) ASIR not 
attributable to HIV (per 100 000) in 2018. ASIR=age-standardised incidence rate.
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of cervical cancer, other factors (particularly screening 
coverage and performance) also affect cervical cancer 
incidence rates, as shown by the variability in incidence 
rates overall.
The increased risk for cervical cancer in women living 
with HIV is a result of a combination of factors.2 Although 
HPV infection is the necessary underlying cause of all 
cervical cancers, women living with HIV are more likely 
to acquire an HPV infection—and less likely to clear 
infection—than are women without HIV, both factors 
contributing to higher rates of persistent HPV infection 
in this population.12,13 Furthermore, HIV has an indirect 
role in oncogenesis, mainly via immune suppression, 
enhancing the effects of high-risk HPV.14 This role is 
highlighted by evidence that cervical cancer is associated 
with a lower CD4 cell count and no ART among women 
living with HIV.15 Due to these synergistic actions, in 
countries with a high prevalence of both HPV and HIV 
infections, the cervical cancer burden is substantially 
raised, particularly among women not on ART.15 Not only 
does HIV increase the risk for cervical cancer but also it 
increases rates of recurrence after treatment of precancer16 
and reduces life expectancy.17 In a prospective study from 
Botswana,17 women living with HIV with cervical cancer 
were more likely to die from this malignant disease than 
were women without HIV infection, even after adjusting 
for disease stage and other relevant variables. Survival 
disparities were even more pronounced for early-stage 
disease.17
Cervical cancer screening followed by adequate 
management and HPV vaccination are two prevention 
tools recommended by WHO that are highly effective, 
with cost-effectiveness of US$100 or less per disability-
adjusted life-year averted in LMICs. This cost places 
these interventions among global so-called best buys 
for non-communicable disease prevention.18 Globally, 
only a third of girls live in countries that have introduced 
the HPV vaccine, with LMICs the least likely to offer 
the vaccine.19 Increasing HPV vaccination coverage in 
countries with a high burden of cervical cancer attri-
butable to HIV is a critical priority. Furthermore, some 
areas with the highest cervical cancer burden, including 
among women living with HIV, are those where 
population-wide screening coverage is low.20 Of the 
ten countries with the highest absolute burden of cervical 
cancer associated with HIV, seven had rolled out 
national HPV immunisation programmes, with full-dose 
coverage ranging from 25% to 80% by 2019.20,21 In the 
same year, only four countries had ongoing population-
based screening, but all covered less than 70% of the 
target population.20 Efforts by PEPFAR have led to 
initiation of cervical cancer screening for women living 
with HIV in some countries.22
In the short-term, screening is the main strategy to 
reduce cervical cancer incidence, by detecting pre-
cancerous lesions that can be treated before evolving 
to cancer. Currently, screening strategies recommended 
by WHO comprise visual inspection with acetic acid, 
cytology (conventional or liquid-based), and HPV DNA 
test ing.23 HPV testing shows superior performance when 
compared with cytology or visual inspection with acetic 
acid. Effectiveness at the population level is affected not 
only by the accuracy of the screening method but also by 
its coverage and by treatment uptake.
Women living with HIV with access to care have clinical 
appointments at least every 6 months, which provides an 
opportunity for delivery of cervical cancer screening and 
treatment interventions, alongside appropriate follow-up. 
Methods to reach women who would not otherwise 
partici pate in screening could greatly improve partici-
pation. Self-sampling of cervical specimens has shown 
promising results and might be applicable in some 
settings.24 Our findings suggest that in settings with high 
HIV prevalence, integration of cervical cancer screening, 
treatment, and referral systems within HIV services could 
have a positive prevention effect on a large proportion of 
cervical cancers.25 Due to the increased risk for cervical 
cancer, specific guidelines for women living with HIV 
have been issued by WHO26 and are being updated. More 
data are needed on the relative performance of different 
implementation approaches, particularly in LMICs.
Over the longer term, HPV vaccination has a key role 
in the prospect of eliminating cervical cancer. The first 
publicly funded national HPV vaccination programmes 
were implemented in 2006 and by October, 2020, 57% of 
countries worldwide had introduced HPV vaccination.19 
Regions that were the first to implement HPV vaccination 
programmes have already reported benefits, which 
include decreased prevalence of HPV types 16 and 18 
infection and declines in the incidence of genital warts 
and of precancerous lesions among young women.27 
A reduction in the incidence of cervical cancer will take 
longer to be detectable and its extent will be largely 
dependent on vaccination uptake.
WHO recommended that HPV vaccination strategies 
target young girls aged 9–14 years, before sexual debut, to 
ensure the highest level of protection.28 However, 
inequalities in access are striking, and only a third of 
girls aged 10 years were living in countries that had 
implemented HPV vaccination by 2019.29 Therefore, 
many girls living in countries with a high cervical cancer 
burden attributable to HIV remain unprotected against 
HPV infection. Expansion of HPV vaccination to areas 
with high HIV prevalence is especially important to 
achieve long-term reductions in the overall cervical 
cancer burden in those settings, as future birth cohorts 
might continue to be at high risk of HIV infection.
Trials of HPV vaccination in people living with HIV 
have shown its safety and indicate that the vaccine is 
immunogenic in this population.28,30,31 The public health 
benefit of vaccinating older adolescents and young 
women living with HIV, in view of their higher risk for 
cervical cancer, needs to be investigated further, since 
most new HIV infections are acquired sexually and, 
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therefore, exposure to HPV infection might have already 
occurred.
The fraction and incidence of cervical cancer attri-
butable to HIV offers a picture of how the burden of 
cervical cancer would be affected by removal of HIV as a 
risk factor in an ideal scenario. This insight clearly brings 
into focus the importance of HIV prevention measures 
on the future burden of cervical cancer in sub-Saharan 
Africa. Early diagnosis of HIV infection and timely 
initiation of ART might also contribute to reducing the 
cervical cancer burden among women living with HIV. 
In a meta-analysis,15 ART (vs no ART) was associated with 
lower prevalence of high-risk HPV and significantly 
lowered the risk of cervical cancer among women living 
with HIV.32
The data presented in this study have limitations, 
arising from two main sources. The first limitation of the 
data is that, although we calculated a pooled overall 
RR estimate, statistical heterogeneity of the included 
studies was considerable. Nonetheless, we decided to 
pool the data because part of this heterogeneity could be 
accounted for by differences in access to early diagnosis 
and ART and by the background cervical cancer risk in 
the studied populations, including the availability and 
uptake of cervical cancer screening. Moreover, we did not 
find substantial regional variations, differences between 
risk measures (RR, OR, or SIR), or changes in degrees of 
bias that would justify stratifying the RR for our 
estimates. Furthermore, 11 of the 24 included studies 
were registry linkage studies, providing SIRs as a 
measure of risk for which the comparison group was the 
general population (including women living with HIV). 
This could have led to an underestimation of risk in a 
high HIV prevalence setting, where women living with 
HIV would contribute to a considerable share of cases in 
the general population.33 With the exception of Uganda, 
regions where registry linkage studies were done have a 
low HIV prevalence. Hence, it is unlikely that the SIRs 
were substantially underestimated due to use of the 
general population as a comparison group. On the other 
hand, most registry linkage studies were done in high-
income areas where population-wide screening for 
cervical cancer is in place and women living with HIV 
generally have improved access to screening, which 
might have attenuated the SIRs. Due to scant information 
on exposures available in registry linkage studies, most 
of the SIR estimates were solely adjusted by age. 
Therefore, other relevant risk factors for cervical cancer 
(eg, smoking, parity, and oral contraceptive use) were not 
considered, possibly resulting in an overestimation of 
risk. This overestimation is apparent in the subgroup 
analyses, in which registry linkage studies tended to 
provide higher estimates than did cohort studies and 
other study designs, after adjusting for other variables. 
Since HIV and HPV are strongly associated due to their 
common transmission route (sexual contact), there is a 
tendency for PAFs to be overestimated, particularly in 
countries with the highest prevalence of HIV infection. 
Nevertheless, without suitable data to disentangle this 
interaction, the provided estimates are, currently, the 
best possible approximation of the excess cervical cancer 
burden attributable to HIV. Furthermore, estimates of 
the proportion of cervical cancer cases diagnosed among 
women living with HIV are unaffected by this 
methodological consideration.
The second limitation of the data is that our analyses 
were based on cervical cancer and HIV estimates8,10 
which, although based on the best available data, might 
not be accurate for countries with insufficient surveillance 
information. Typically, these are the countries identified 
in this study as having high HIV-related cervical cancer 
burden.
A final limitation of our study is that we do not show 
estimates stratified by age, conscious of the fact that 
such an approach requires a systematic appraisal of 
appropriate age-specific RR estimates. Only one of the 
24 studies included in the meta-analysis provided age-
stratified RRs.34 This study reported an overall RR of 6, 
consistent with our findings, but reported decreasing 
RRs by age group. Although this age effect is the topic of 
further analyses and validation, it is beyond the scope of 
the present study.
In conclusion, our study presents the first global 
estimates of cervical cancer attributable to HIV. We 
show that women living with HIV have a six-fold higher 
risk of developing cervical cancer compared with 
women without HIV infection. In view of this increased 
risk, we estimate that nearly 5% of all cervical cancer 
cases worldwide are attributable to HIV infection. This 
attribu table fraction varies greatly by region and is 
highest across southern and eastern Africa and some 
countries in western Africa, where coverage of HPV 
vaccination, and of cervical cancer screening and 
treatment for all women and girls, is suboptimal. It is 
important to improve access to cervical cancer 
prevention for all women in all settings, but particularly 
in countries where access to health services is difficult 
and HIV prevalence is high. Focusing on both cervical 
cancer prevention and HIV prevention, including 
integration of cervical cancer screening and treatment 
with HIV services, can optimise benefits in countries 
hardest hit by both epidemics. Such an approach in 
countries with the highest burden of HIV-attributable 
cervical cancer will contribute substantially to delivering 
on the WHO 2030 scale-up targets of 90% coverage of 
vaccination of girls, 70% coverage of screening, and 
90% coverage of treatment leading to elimination of 
cervical cancer as a major public health problem in the 
future and reversal of the widening disparities in the 
disease burden seen today.
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